Clinical trial · Observational
Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia
Identification of Target Genes for Diagnosis and Prognosis of AML Using a Custom-Design Microarray
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify genes related to cancer. It may also help doctors diagnose cancer and predict how patients will respond to treatment. PURPOSE: This research study is identifying cancer-related genes in blood and/or bone marrow samples from patients with acute myeloid leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| microarray analysis | Genetic | — | UNRESOLVED |
| polymerase chain reaction | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Group 1
- description
- This is a CALGB Leukemia Tissue Bank project makes use of tissue from patients who have previously provided their consent. Diagnostic samples from patients enrolled on CALGB AML treatment studies (eg, CALGB 9621, 9710, and 19808) and who have been registered on the companion Leukemia Tissue Bank Protocol CALGB 9665 were used.
- interventionNames
- Genetic: microarray analysis
- Genetic: polymerase chain reaction
Primary outcomes (4)
- measure
- Correlation of increased or decreased expression of same transcripts with disease outcome
- timeFrame
- baseline
- measure
- Minimum number of genes that can be used for precise diagnosis of each of the three subtypes of acute myeloid leukemia
- timeFrame
- baseline
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
* Enrolled on CALGB acute myeloid leukemia (AML) treatment studies AND concurrently enrolled on Leukemia Tissue Bank Protocol CALGB-9665 * Short-term or long-term survivor * Bone marrow and/or peripheral blood obtained at diagnosis * Leukemia is one of the following cytogenetic subtypes: * t(8;21) * t(15;17) * inv(16)
References
Publications (0)
Data not yet available